Atorvastatin calcium: EFFICACY(2)
Comparative trials with other HMG-CoA reductase inhibitors
The efficacy and safety of atorvastatin have been compared with those of available HMG-CoA reductase inhibitors. In three studies, atorvastatin was compared individually with lovastatin, pravastatin and simvastatin over one year in patients with mild to moderate hypercholesterolemia . These were multicentre, double-blind, randomized trials conducted in North America (lovastatin study), Europe (pravastatin study) and Australia (simvastatin study). Following a six-week placebo baseline period, patients were randomly assigned to receive atorvastatin 10 mg/day, lovastatin 20 mg/day, pravastatin 20 mg/day or simvastatin 10 mg/day. Your turn to find out more about the possibility to get and pay tons less.
If patients did not meet their LDL-C target levels, established according to United States National Cholesterol Education Program (NCEP) guidelines, European Atherosclerosis Society (EAS) guidelines or a fixed target of less than 3.4 mmol/L, as was the case in the pravastatin and simvastatin studies, the dose of medication was doubled at four months and maintained for the duration of the trial.